NASDAQ:KTRA Kintara Therapeutics (KTRA) Stock Forecast, Price & News $3.87 -0.01 (-0.26%) (As of 01:29 PM ET) Add Compare Share Share Today's Range$3.87▼$4.2150-Day Range$3.30▼$4.9252-Week Range$2.70▼$15.50Volume3,800 shsAverage Volume76,143 shsMarket Capitalization$6.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Kintara Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.50) to $0.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.37 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Kintara Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.60% of the float of Kintara Therapeutics has been sold short.Short Interest Ratio / Days to CoverKintara Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kintara Therapeutics has recently decreased by 66.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKintara Therapeutics does not currently pay a dividend.Dividend GrowthKintara Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KTRA. Previous Next 2.0 News and Social Media Coverage News SentimentKintara Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kintara Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Kintara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kintara Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.83% of the stock of Kintara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 2.42% of the stock of Kintara Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kintara Therapeutics are expected to grow in the coming year, from ($0.50) to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kintara Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kintara Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Kintara Therapeutics (NASDAQ:KTRA) StockKintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.Read More KTRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTRA Stock News HeadlinesOctober 2, 2023 | finance.yahoo.comKintara Therapeutics to Present at the LD Micro Main Event XVI ConferenceSeptember 25, 2023 | finance.yahoo.comKintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual MeetingOctober 3, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 19, 2023 | seekingalpha.comKintara Therapeutics Non-GAAP EPS of -$9.27September 18, 2023 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate UpdateSeptember 14, 2023 | uk.finance.yahoo.comKTRA - Kintara Therapeutics, Inc.September 5, 2023 | finance.yahoo.comKintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual MeetingAugust 17, 2023 | finance.yahoo.comKintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023October 3, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 9, 2023 | finance.yahoo.comKintara Therapeutics to Present at the Emerging Growth ConferenceAugust 8, 2023 | finance.yahoo.comPresenting on the Emerging Growth Conference on August 9 & 10 Register NowJuly 14, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For July 14, 2023June 30, 2023 | finance.yahoo.comKintara (KTRA) Rises 41% on $2M Grant for Breast Cancer TherapyJune 29, 2023 | benzinga.comKintara Therapeutics Stock Is Trading Higher: What's Driving The Action?June 28, 2023 | finance.yahoo.comKintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001June 16, 2023 | finance.yahoo.comKintara Therapeutics to Participate in the Maxim Group Virtual Healthcare ConferenceMay 19, 2023 | finance.yahoo.comKintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor SocietyMay 12, 2023 | msn.comRecap: Kintara Therapeutics Q3 EarningsMay 11, 2023 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate UpdateMay 8, 2023 | finance.yahoo.comKintara Therapeutics to Present at the Sidoti Micro-Cap Virtual ConferenceMay 1, 2023 | finance.yahoo.comKintara Therapeutics to Present at the Aegis Capital Virtual ConferenceApril 14, 2023 | finance.yahoo.comKintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual MeetingMarch 17, 2023 | ca.finance.yahoo.comThese 4 Biotech Stocks Just Got ‘Fast Track’ Designation GreenlightsMarch 15, 2023 | finance.yahoo.comKintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual MeetingMarch 10, 2023 | finance.yahoo.comKintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023February 14, 2023 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate UpdateJanuary 30, 2023 | finance.yahoo.comKintara Therapeutics to Present at the 2023 BIO CEO & Investor ConferenceSee More Headlines Receive KTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KTRA Company Calendar Last Earnings11/15/2021Today10/03/2023Next Earnings (Estimated)11/08/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KTRA CUSIPN/A CIK1498382 Webwww.kintara.com Phone(858) 350-4364Fax604-608-5685Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,650,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-173.15% Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio1.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($5.86) per share Price / Book-0.68Miscellaneous Outstanding Shares1,750,000Free Float1,662,000Market Cap$6.95 million OptionableNot Optionable Beta1.04 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Robert E. Hoffman B.B.A. (Age 57)CPA, CPA, Pres, CEO, Interim CFO & Chairman Comp: $768.29kDr. Dennis M. Brown B.Sc. (Age 73)M.A., Ph.D., Co-Founder & Chief Scientific Officer Comp: $247.28kMr. Jeffrey A. Bacha B.Sc. (Age 55)M.B.A., Founder Mr. Greg A. JohnsonActing Head of OperationsKey CompetitorsDMK PharmaceuticalsNASDAQ:DMKAdamis PharmaceuticalsNASDAQ:ADMPBiodexa PharmaceuticalsNASDAQ:BDRXApplied Molecular TransportNASDAQ:AMTIPulmatrixNASDAQ:PULMView All Competitors KTRA Stock - Frequently Asked Questions Should I buy or sell Kintara Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KTRA shares. View KTRA analyst ratings or view top-rated stocks. How have KTRA shares performed in 2023? Kintara Therapeutics' stock was trading at $6.89 at the beginning of 2023. Since then, KTRA stock has decreased by 42.4% and is now trading at $3.97. View the best growth stocks for 2023 here. Are investors shorting Kintara Therapeutics? Kintara Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 9,600 shares, a decrease of 66.6% from the August 31st total of 28,700 shares. Based on an average daily trading volume, of 158,400 shares, the short-interest ratio is presently 0.1 days. Currently, 0.6% of the shares of the stock are short sold. View Kintara Therapeutics' Short Interest. When is Kintara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our KTRA earnings forecast. How were Kintara Therapeutics' earnings last quarter? Kintara Therapeutics, Inc. (NASDAQ:KTRA) posted its quarterly earnings results on Monday, November, 15th. The company reported ($8.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.00) by $1.50. When did Kintara Therapeutics' stock split? Shares of Kintara Therapeutics reverse split before market open on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Kintara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN). What is Kintara Therapeutics' stock symbol? Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA." How do I buy shares of Kintara Therapeutics? Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kintara Therapeutics' stock price today? One share of KTRA stock can currently be purchased for approximately $3.97. How much money does Kintara Therapeutics make? Kintara Therapeutics (NASDAQ:KTRA) has a market capitalization of $6.95 million. The company earns $-14,650,000.00 in net income (profit) each year or ($9.49) on an earnings per share basis. How can I contact Kintara Therapeutics? Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.kintara.com. The company can be reached via phone at (858) 350-4364, via email at ir@delmarpharma.com, or via fax at 604-608-5685. This page (NASDAQ:KTRA) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kintara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.